When a biotech names itself Wugen, you know they’re not showing up to play small ball. Headquartered in St. Louis with clinical operations in San Diego, this company is engineering allogeneic, off-the-shelf cell therapies designed to take on cancers that haven’t had a real shot in years. With $115 million in fresh funding led by Fidelity Management & Research Company, joined by RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group, Tybourne Capital Management, and Aisling Capital Management, Wugen just expanded its runway from ambitious to undeniable.
The story started in 2018 at Washington University School of Medicine, where Matthew Cooper, Ph.D., co-founder and Chief Scientific Officer, teamed with scientific co-founders John F. DiPersio, M.D., Ph.D., Todd A. Fehniger, M.D., Ph.D., and Melissa Berrien-Elliott, Ph.D. Their science was built on gene editing and cell therapy platforms that BioGenerator and Cortex Innovation Community helped spin out. Today, Wugen isn’t just translating academic brilliance, it’s scaling it with the kind of leadership that can deliver. Kumar Srinivasan, Ph.D., MBA is steering as President and CEO, Cherry T. Thomas, M.D. is driving clinical execution as Chief Medical Officer, and Keith Vendola, M.D., MBA is running finance with precision, while Matthew Cooper keeps the science sharp at the core.
WU-CART-007, Wugen’s lead candidate, is aimed straight at relapsed and refractory T-ALL/T-LBL, a segment where survival odds are stacked against patients. Phase 1 / Phase 2 trials delivered a 91% overall response rate with 73% complete remission at the recommended dose. The pivotal Phase 2 T-RRex trial kicked off in March 2025, and with FDA designations across RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease, plus EMA’s PRIME status, regulators are signaling urgency. That’s rare air.
The tech is as fierce as the data. Wugen’s allogeneic CAR-T therapies use CRISPR / Cas9 edits to knock out CD7 and TRAC, solving the fratricide and graft-versus-host puzzle that has kept others stuck. Off-the-shelf manufacturing means patients don’t wait months while their disease advances; they get a therapy that’s ready on demand. Layer in Moneta, their memory NK platform, and you see a pipeline designed for more than just blood cancers. The expansion potential into autoimmune disease is baked in.
This raise fuels more than trial enrollment; it’s about manufacturing scale-up, regulatory prep, and positioning for a 2027 Biologics License Application. If Wugen lands the first approved allogeneic CD7-targeted CAR-T, they’ll be playing in a $1 billion market that desperately needs innovation. For patients who’ve been told “there’s nothing left,” Wugen’s science is the counterpunch.
The capital syndicate backing them isn’t chasing hype. They’re betting that Kumar Srinivasan and his team can deliver therapies that hit both the clinic and the market with impact. And if momentum is the most valuable currency in biotech, Wugen just banked it in spades.
